Scandinavian ChemoTech AB Series B
Scandinavian ChemoTech AB (publ), a medical technology company, engages in the radiation physics, surgical oncology, and clinical development in Sweden and internationally. It operates in two divisions, Human Care and Animal Care. The company offers IQWave, an electroporation that generates a tumour-specific electrical stimulation; and veterinary medicines under the vetIQur name. Scandinavian Che… Read more
Scandinavian ChemoTech AB Series B (CMOTEC-B) - Net Assets
Latest net assets as of September 2025: Skr6.19 Million SEK
Based on the latest financial reports, Scandinavian ChemoTech AB Series B (CMOTEC-B) has net assets worth Skr6.19 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr17.38 Million) and total liabilities (Skr11.18 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr6.19 Million |
| % of Total Assets | 35.64% |
| Annual Growth Rate | 62.6% |
| 5-Year Change | -35.25% |
| 10-Year Change | 588.44% |
| Growth Volatility | 672.76 |
Scandinavian ChemoTech AB Series B - Net Assets Trend (2014–2024)
This chart illustrates how Scandinavian ChemoTech AB Series B's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Scandinavian ChemoTech AB Series B (2014–2024)
The table below shows the annual net assets of Scandinavian ChemoTech AB Series B from 2014 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr5.98 Million | -45.79% |
| 2023-12-31 | Skr11.03 Million | -21.16% |
| 2022-12-31 | Skr13.99 Million | -41.50% |
| 2021-12-31 | Skr23.92 Million | +158.95% |
| 2020-12-31 | Skr9.24 Million | -5.07% |
| 2019-12-31 | Skr9.73 Million | -52.53% |
| 2018-12-31 | Skr20.50 Million | +99.23% |
| 2017-12-31 | Skr10.29 Million | -29.46% |
| 2016-12-31 | Skr14.58 Million | +1578.88% |
| 2015-12-31 | Skr868.64K | +1777.36% |
| 2014-12-31 | Skr46.27K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Scandinavian ChemoTech AB Series B's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 1371140600.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | Skr11.67 Million | 195.18% |
| Other Comprehensive Income | Skr-108.87 Million | -1820.55% |
| Other Components | Skr116.89 Million | 1954.75% |
| Total Equity | Skr5.98 Million | 100.00% |
Scandinavian ChemoTech AB Series B Competitors by Market Cap
The table below lists competitors of Scandinavian ChemoTech AB Series B ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
ANAX Metals Ltd
AU:ANX
|
$5.11 Million |
|
Agereh Technologies Inc
V:AUTO
|
$5.11 Million |
|
OneMeta AI
OTCQB:ONEI
|
$5.11 Million |
|
DS Sigma Holdings Berhad
KLSE:0269
|
$5.12 Million |
|
Mannatech Incorporated
NASDAQ:MTEX
|
$5.10 Million |
|
Ni Hsin Resources Bhd
KLSE:7215
|
$5.10 Million |
|
DeepSpatial Inc.
PINK:DSAIF
|
$5.10 Million |
|
ARB IOT Group Limited Ordinary Shares
NASDAQ:ARBB
|
$5.10 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Scandinavian ChemoTech AB Series B's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 11,031,000 to 5,980,000, a change of -5,051,000 (-45.8%).
- Net loss of 13,717,000 reduced equity.
- Share repurchases of 8,546,000 reduced equity.
- New share issuances of 8,546,000 increased equity.
- Other comprehensive income decreased equity by 20,971,000.
- Other factors increased equity by 29,637,000.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-13.72 Million | -229.38% |
| Share Repurchases | Skr8.55 Million | -142.91% |
| Share Issuances | Skr8.55 Million | +142.91% |
| Other Comprehensive Income | Skr-20.97 Million | -350.69% |
| Other Changes | Skr29.64 Million | +495.6% |
| Total Change | Skr- | -45.79% |
Book Value vs Market Value Analysis
This analysis compares Scandinavian ChemoTech AB Series B's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 15.50x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 152.11x to 15.50x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | Skr0.03 | Skr3.97 | x |
| 2014-12-31 | Skr0.03 | Skr3.97 | x |
| 2015-12-31 | Skr0.76 | Skr3.97 | x |
| 2016-12-31 | Skr9.98 | Skr3.97 | x |
| 2017-12-31 | Skr7.03 | Skr3.97 | x |
| 2018-12-31 | Skr6.28 | Skr3.97 | x |
| 2019-12-31 | Skr2.37 | Skr3.97 | x |
| 2020-12-31 | Skr1.88 | Skr3.97 | x |
| 2021-12-31 | Skr2.76 | Skr3.97 | x |
| 2022-12-31 | Skr1.40 | Skr3.97 | x |
| 2023-12-31 | Skr0.79 | Skr3.97 | x |
| 2024-12-31 | Skr0.26 | Skr3.97 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Scandinavian ChemoTech AB Series B utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -229.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -208.91%
- • Asset Turnover: 0.49x
- • Equity Multiplier: 2.24x
- Recent ROE (-229.38%) is below the historical average (-107.23%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | -16.80% | 0.00% | 0.00x | 1.00x | Skr-11.90K |
| 2014 | -60.81% | 0.00% | 0.00x | 1.42x | Skr-32.76K |
| 2015 | -135.94% | -8498.88% | 0.00x | 7.66x | Skr-1.27 Million |
| 2016 | -55.81% | -390.48% | 0.12x | 1.15x | Skr-9.60 Million |
| 2017 | -80.99% | -30582.56% | 0.00x | 1.25x | Skr-9.36 Million |
| 2018 | -23.41% | -856.61% | 0.02x | 1.11x | Skr-6.85 Million |
| 2019 | -129.36% | -2263.49% | 0.03x | 1.80x | Skr-13.56 Million |
| 2020 | -126.29% | -8903.82% | 0.01x | 1.73x | Skr-12.59 Million |
| 2021 | -74.19% | -36210.20% | 0.00x | 1.08x | Skr-20.13 Million |
| 2022 | -162.56% | -4808.88% | 0.02x | 1.55x | Skr-24.15 Million |
| 2023 | -191.20% | -747.38% | 0.19x | 1.35x | Skr-22.19 Million |
| 2024 | -229.38% | -208.91% | 0.49x | 2.24x | Skr-14.31 Million |
Industry Comparison
This section compares Scandinavian ChemoTech AB Series B's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Scandinavian ChemoTech AB Series B (CMOTEC-B) | Skr6.19 Million | -16.80% | 1.81x | $5.10 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |